Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
IPO Year: 2013
Exchange: NASDAQ
Website: chimerix.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/23/2023 | $7.00 | Outperform | Robert W. Baird |
9/7/2022 | $7.00 | Overweight | CapitalOne |
12/22/2021 | $21.00 → $24.00 | Buy | HC Wainwright & Co. |
11/22/2021 | $19.00 → $21.00 | Buy | HC Wainwright & Co. |
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a biopharmaceutical company with
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years,
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2024 and provided an operational
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, wit
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET. An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a biopharmaceutical company with a mission to develop medicines that mea
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years,
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
4 - CHIMERIX INC (0001117480) (Issuer)
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo
DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. "We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization," said Mike Andriole, Chief Executive Officer of Chimerix. "Tom's in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts
DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today appointed Christopher L. Jordan as Vice President, Regulatory Affairs. "We are pleased to announce the addition of Christopher Jordan to our leadership team as VP of Regulatory Affairs. Christopher brings over 30 years of pharmaceutical experience across various stages of product development. Some on our management team have had the pleasure of working with Christopher several years ago at Endocyte and Novartis where he recently led the regulatory strategy and
DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective immediately. Ms. Vakiener currently serves as Chief Commercial Officer of Epizyme Inc. "We are thrilled to welcome Vicki to our Board of Directors. She brings a tremendous amount of oncology commercial leadership experience to our Board as we advance our late stage programs," said Mike Sherman, President and Chief Executive Officer of Chimerix. "The diversity of Vicki's capabilities across every aspect of t
S-8 - CHIMERIX INC (0001117480) (Filer)
10-Q - CHIMERIX INC (0001117480) (Filer)
8-K - CHIMERIX INC (0001117480) (Filer)
8-K - CHIMERIX INC (0001117480) (Filer)
8-K - CHIMERIX INC (0001117480) (Filer)
EFFECT - CHIMERIX INC (0001117480) (Filer)
10-Q - CHIMERIX INC (0001117480) (Filer)
8-K - CHIMERIX INC (0001117480) (Filer)
DEFA14A - CHIMERIX INC (0001117480) (Filer)
DEF 14A - CHIMERIX INC (0001117480) (Filer)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G - CHIMERIX INC (0001117480) (Subject)
SC 13G - CHIMERIX INC (0001117480) (Subject)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13G/A - CHIMERIX INC (0001117480) (Subject)
SC 13D - CHIMERIX INC (0001117480) (Subject)
SC 13G - CHIMERIX INC (0001117480) (Subject)
SC 13G - CHIMERIX INC (0001117480) (Subject)
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose Limiting Toxicity to Date – – Dordaviprone Filed for Provisional Determination with Therapeutic Goods Administration in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2024 and provided an operational
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update. "Following strong clinical development in 2
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update. "The third quarter was marked by strong progress across our first-
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5615320. A live audio webcast of the call will also be avai
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in First Half 2024 – – Capital Available to Fund Operations is $233 Million as of June 30, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update. "I am thrilled to begin
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 3, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business overview. To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 8015897. A live audio webcast of the call will also be available on
– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update. "2023 is off to a strong start and has been highlighted by multiple presentations of data in support of our imipridone platform durin
Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00
CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously
HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $21.00 from $19.00 previously
HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $19.00 from $18.00 previously
HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $18.00 from $16.00 previously
Maxim Group initiated coverage of Chimerix with a rating of Buy and set a new price target of $20.00
Cowen resumed coverage of Chimerix with a rating of Outperform and set a new price target of $18.00 from $10.00 previously
Wedbush initiated coverage of Chimerix with a rating of Outperform and set a new price target of $14.00
Jefferies initiated coverage of Chimerix with a rating of Buy and set a new price target of $21.00
Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 4.17 percent decrease over losses of $(0.24) per share from the same period last year.
https://twitter.com/DrTedros/status/1778423967105139108
HC Wainwright & Co. analyst Edward White reiterates Chimerix (NASDAQ:CMRX) with a Buy and maintains $11 price target.
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 16.67 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $60.00 thousand by 93.33 percent. This is a 99.51 percent decrease over sales of $814.00 thousand the same period last year.
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. • NB Bancorp (NASDAQ:NBBK) is likely to report earnings for its Fiscal Year 2023. • Verona Pharma (NASDAQ:VRNA) is projected to report quarterly loss at $0.26 per share on revenue of $0. • iHuman (NYSE:IH) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ:ARGX) is estimated to report quarterly loss at $1.71 per share on revenue of $364.75 million. • Titan Intl (NYSE:TWI) is expected to report quarterly earnings at $0.28 per share on revenue of $413.57 million. • Canadian Imperial Bank (NYSE:CM) is projected to repo
Chimerix (NASDAQ:CMRX) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement. Analysts estimate that Chimerix will report an earnings per share (EPS) of $-0.24. Chimerix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company missed EPS by $0.04, which was followed by a 8.16% increase in the share price th
https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&utm_campaign=trueanthem&utm_medium=trueanthem&utm_source=twitterThe World Health Organization is "very worried" about the spread of a severe form of mpox that has killed nearly 600 people, mainly children, in the Democratic Republic of Congo this year, a senior official said.The country has reported over 13,000 cases in 2023, more than twice as many as during the last peak in 2020, with the disease occurring in almost every province. The WHO is working with the authorities on the response and a risk assessment.On Thursday, the U.S. Centers for Disease C